Genentech’s food allergy medication gets priority review nod from the FDA

Genentech’s Xolair scored a priority review from the FDA on Wednesday for the reduction of allergic reactions in adult and pediatric patients 1 year and older, the company said, with the agency expected to make a decision in the first quarter of 2024.

If it’s approved,…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks